Alkomiet H.
- Country
- Germany
- Department
- Klinik für Psychiatrie, Psychotherapie und Psychosomatik
Research Overview
- Efficacy of Xanomeline/Trospium in Adults with Schizophrenia for the Treatment of Cognitive Impairment: A Prospective Multicenter Study
- Efficacy and Safety of AP707 in Patients with Borderline Personality Disorder: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial
- Evaluation of Intensified Pharmacological Regimen with Clozapine and Drug Combination in Schizophrenia Patients Experiencing First-Line Treatment Failure
Data & Insights
Has run more than one trial at 14 of 39 partner sites.
Specializations
Psychiatric Disorders
The investigator specializes in treating complex psychiatric conditions, with a primary focus on schizophrenia spectrum disorders and related cognitive dysfunctions.
- Schizophrenia
- Schizoaffective Disorder
- Schizophreniform Disorder
Their research extends to major mood disorders including bipolar depression and major depressive disorder.
Treatment Approaches
The investigator explores innovative therapeutic strategies combining pharmacological interventions with physical exercise to enhance treatment outcomes.
- Early-Intensified Pharmacological Treatment
- Aerobic Exercise Integration
- First-line Treatment Optimization
Their work addresses treatment resistance and first-time treatment failures in psychiatric conditions.
Cognitive Function
The investigator studies cognitive enhancement strategies in psychiatric disorders, particularly focusing on memory and functional improvement.
- Working Memory Performance
- Global Assessment of Functioning
- Myelin Plasticity
Their research evaluates cognitive outcomes through specialized assessment tools and functional measurements.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.